Skip to main content
. 2021 Mar 6;13(5):1135. doi: 10.3390/cancers13051135

Figure 2.

Figure 2

Dinaciclib is effective at inhibiting growth of primary endometrial tumor cells isolated from EC patients. Dose–response following 72 h of treatments with dinaciclib in tumor cells isolated from eight EC tumors, labeled in the graphs as B1 to B8 (a–h). Viability was measured using a RealTime-Glo MT Cell Viability Assay and normalized to vehicle controls. (i) A comparison of the IC50s of tumor cells derived from Type I (B1, B2, B5, B7, B8) and II (B3, B4, B6) tumors. (j) Immunohistochemical (IHC) panel showing, from left to right, ER, p53, and H and E (hematoxylin and eosin), staining of EC biopsy tissue, Scale Bar is 300 μm. Statistical significance was calculated using the unpaired t-test. ns = not significant.